Who are Detectnet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pegvisomant/ Sandostatin LAR, Neuraceq, Posluma, Flyrcado, FLURPIRIDAZ F 18, Ioflupane I 123.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/copper-dotatate-cu-64.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Detectnet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Detectnet (copper dotatate Cu-64) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioactive Diagnostic Agent [EPC]. Area: Oncology.

marketed Radioactive Diagnostic Agent [EPC] somatostatin receptors, particularly SSTR2 Oncology Live · refreshed every 30 min

Target snapshot

Detectnet (copper dotatate Cu-64) — Radiomedix. Copper Cu 64 dotatate binds to somatostatin receptors, particularly SSTR2, on neuroendocrine tumor cells, allowing PET imaging.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Detectnet TARGET	copper dotatate Cu-64	Radiomedix	marketed	Radioactive Diagnostic Agent [EPC]	somatostatin receptors, particularly SSTR2	2020-01-01
Pegvisomant/ Sandostatin LAR	Pegvisomant/ Sandostatin LAR	Pfizer	marketed	Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR)	Growth hormone receptor (pegvisomant); somatostatin receptors, particularly SSTR2 and SSTR5 (octreotide)
Neuraceq	FLORBETABEN	Life Molecular	marketed	Radioactive Diagnostic Agent [EPC]		2025-01-01
Posluma	FLOTUFOLASTAT	Blue Earth	marketed	Radioactive Diagnostic Agent [EPC]		2025-01-01
Flyrcado	FLURPIRIDAZ	Ge Hlthcare	marketed	Radioactive Diagnostic Agent [EPC]		2024-01-01
FLURPIRIDAZ F 18	FLURPIRIDAZ F 18		marketed	Radioactive Diagnostic Agent [EPC]		2024-01-01
Ioflupane I 123	IOFLUPANE	Ge Hlthcare Inc	marketed	Radioactive Diagnostic Agent [EPC]	Dopamine transporter (DaT)	2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-08-23 — Detectnet · 10383961 · US
2032-08-23 — Detectnet · 10159759 · US
2032-08-23 — Detectnet · 11160888 · US

Sponsor landscape (Radioactive Diagnostic Agent [EPC] class)

· 6 drugs in this class
GE HealthCare · 3 drugs in this class
Blue Earth · 2 drugs in this class
Avid Radiopharms Inc · 2 drugs in this class
Ge Hlthcare Inc · 2 drugs in this class
Ge Healthcare · 1 drug in this class
Ge Hlthcare · 1 drug in this class
Lantheus Medical Imaging · 1 drug in this class
Life Molecular · 1 drug in this class
Mcprf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Detectnet — Competitive Intelligence Brief. https://druglandscape.com/ci/copper-dotatate-cu-64. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing